Trial Profile

A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IM 3050 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Immunome

Most Recent Events

20 Jul 2026 According to an Immunome media release, first patient has been dosed in this trial.
18 Jun 2026 Planned initiation date changed from 1 Apr 2026 to 1 Jun 2026.
12 May 2026 According to an Immunome media release, Immunome initiated the first clinical trial site for a Phase 1 trial of IM-3050 in patients with FAP-expressing solid tumors.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com